Hospital
ST Martin Hospital, INC.
ST Martin Hospital, INC. was paid $12.79M by Medicaid between Jan 2018 and Dec 2024, across 173 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoST MARTIN HOSPITAL, INC.
BREAUX BRIDGE, LA 70517
BREAUX BRIDGE, LA 70517
33aNPI1437482817assigned 09/16/2009
33bProvider typeCritical Access Hospital
28Total paid$12.79M
24GClaims305,396
24DCodes billed173
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Louisiana
Rank by total paid#3 of 40
Median peer was paid$3.19M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,095 | $1.38M | |
| 2019 | 38,881 | $1.20M | |
| 2020 | 32,386 | $942K | |
| 2021 | 49,860 | $1.72M | |
| 2022 | 55,237 | $2.52M | |
| 2023 | 58,012 | $3.37M | |
| 2024incomplete | 32,925 | $1.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 33,803 | 31,699 | $3.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 20,873 | 19,226 | $2.67M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 6,837 | 6,178 | $919K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.8% | 13,612 | 11,529 | $612K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 6,445 | 6,085 | $580K |
| 0240U | 2.5% | 3,513 | 3,090 | $315K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.6% | 1,814 | 1,705 | $207K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 3,761 | 3,431 | $198K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.5% | 6,086 | 1,239 | $187K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 4,161 | 3,382 | $185K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 451 | 420 | $184K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.4% | 1,669 | 1,524 | $181K |
161 more codes
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 1.2% | 101 | $156K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 2,970 | $144K |
| 80053 | Comprehensive metabolic panel | 1.0% | 17,930 | $132K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 4,667 | $128K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,256 | $112K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 161 | $102K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,247 | $95K |
| 80050 | General health panel | <1% | 2,265 | $95K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,302 | $94K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,460 | $91K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,543 | $91K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,884 | $83K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 108 | $79K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,345 | $78K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,616 | $76K |
| 80061 | Lipid panel | <1% | 5,885 | $67K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,505 | $66K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,364 | $66K |
| J3490 | Unclassified drugs | <1% | 7,429 | $64K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 508 | $60K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,759 | $58K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,602 | $55K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,444 | $54K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 722 | $45K |
| 81025 | <1% | 5,645 | $42K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,212 | $42K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,198 | $41K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,243 | $39K |
| 81001 | <1% | 15,865 | $35K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 43 | $35K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,296 | $31K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 101 | $27K |
| 86780 | <1% | 2,394 | $27K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,125 | $24K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 852 | $22K |
| 87449 | <1% | 1,804 | $22K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 354 | $21K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 620 | $19K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,511 | $17K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,211 | $16K |
| 84439 | <1% | 1,929 | $16K | |
| 86803 | <1% | 1,280 | $15K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 297 | $14K |
| 86762 | <1% | 1,154 | $14K | |
| 74018 | <1% | 57 | $13K | |
| 86787 | <1% | 1,126 | $12K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,243 | $12K |
| 87400 | <1% | 916 | $11K | |
| 84484 | <1% | 1,688 | $11K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 451 | $11K |
| 87340 | <1% | 1,242 | $11K | |
| 86850 | <1% | 1,435 | $10K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 214 | $10K |
| 87081 | <1% | 1,519 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 268 | $10K |
| 87088 | <1% | 1,559 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 464 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 924 | $9K |
| 85027 | <1% | 1,829 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,545 | $9K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 241 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 56 | $8K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 155 | $8K |
| 83690 | <1% | 1,276 | $6K | |
| 90686 | <1% | 91 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 259 | $5K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 99 | $5K |
| 74019 | <1% | 53 | $4K | |
| 84702 | <1% | 268 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 45 | $4K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 70 | $3K |
| 82607 | <1% | 245 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 116 | $3K |
| 86900 | <1% | 1,305 | $3K | |
| 86901 | <1% | 1,306 | $3K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 286 | $3K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 221 | $3K |
| A9150 | Non-prescription drugs | <1% | 633 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $3K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 54 | $3K |
| 82553 | <1% | 458 | $3K | |
| 83880 | <1% | 145 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 488 | $2K |
| 83735 | <1% | 636 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 43 | $2K |
| 82550 | <1% | 604 | $2K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 278 | $2K |
| 72100 | <1% | 26 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 119 | $2K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 293 | $2K |
| 90715 | <1% | 14 | $2K | |
| 82950 | <1% | 384 | $2K | |
| 82043 | <1% | 338 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 680 | $1K |
| 73030 | <1% | 15 | $1K | |
| 83021 | <1% | 102 | $1K | |
| 82947 | <1% | 351 | $1K | |
| 82077 | <1% | 113 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 241 | $1K |
| 84153 | <1% | 77 | $1K | |
| 83020 | <1% | 113 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 13 | $1K |
| 84144 | <1% | 68 | $1K | |
| 86592 | <1% | 228 | $958.47 | |
| 82150 | <1% | 193 | $898.38 | |
| 86141 | <1% | 89 | $738.57 | |
| 97161 | <1% | 12 | $707.28 | |
| 82570 | <1% | 160 | $704.48 | |
| 83550 | <1% | 68 | $679.78 | |
| 87077 | <1% | 120 | $675.66 | |
| 85660 | <1% | 124 | $671.02 | |
| 82728 | <1% | 38 | $605.88 | |
| 87184 | <1% | 142 | $578.88 | |
| 80074 | <1% | 13 | $523.93 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 22 | $518.33 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 13 | $510.15 |
| 72040 | <1% | 12 | $499.04 | |
| 73130 | <1% | 14 | $493.20 | |
| 83540 | <1% | 69 | $473.41 | |
| 81511 | <1% | 40 | $433.73 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 56 | $338.95 |
| 87420 | <1% | 24 | $329.72 | |
| 82677 | <1% | 12 | $328.35 | |
| 84436 | <1% | 51 | $315.84 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 32 | $314.67 |
| 80320 | <1% | 71 | $300.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 26 | $293.45 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 29 | $283.19 |
| 80179 | <1% | 19 | $279.60 | |
| 80305 | <1% | 24 | $277.20 | |
| 82105 | <1% | 12 | $227.81 | |
| 84481 | <1% | 19 | $215.29 | |
| 86336 | <1% | 12 | $211.64 | |
| 85610 | <1% | 120 | $208.91 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 14 | $169.13 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 26 | $168.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 62 | $129.96 |
| 99152 | <1% | 15 | $129.66 | |
| 81003 | <1% | 80 | $119.25 | |
| 85379 | <1% | 13 | $100.48 | |
| 86140 | <1% | 14 | $91.52 | |
| 84479 | <1% | 14 | $75.84 | |
| 80076 | <1% | 12 | $65.36 | |
| 82962 | <1% | 23 | $54.23 | |
| 82270 | <1% | 14 | $52.56 | |
| 82272 | <1% | 15 | $50.76 | |
| 99386 | <1% | 13 | $44.29 | |
| 3016F | 0% | 27 | $0.00 | |
| 87631 | 0% | 185 | $0.00 | |
| 02404 | 0% | 73 | $0.00 | |
| 3078F | 0% | 40 | $0.00 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 12 | $0.00 |
| 3077F | 0% | 21 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 384 | $0.00 |
| 3080F | 0% | 13 | $0.00 | |
| 3075F | 0% | 18 | $0.00 | |
| 3074F | 0% | 58 | $0.00 | |
| 3079F | 0% | 55 | $0.00 | |
| 1170F | 0% | 99 | $0.00 | |
| 99385 | 0% | 29 | $0.00 | |
| 3008F | 0% | 100 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCALLECOD, DAVID (AUTHORIZED DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| University Hospital & Clinics, INC. | Lafayette, LA | $60.90M |
| Acadia General Hospital, INC. | Crowley, LA | $8.42M |
| Kaplan General Hospital, INC. | Kaplan, LA | $3.98M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.